AstraZeneca plans to invest $50bn in the US by 2030 for drug manufacturing and R&D, building a facility in Virginia for weight management and metabolic products. This investment aims to reach $80bn in revenue by 2030 and create new jobs. The company will also expand R&D facilities and establish new centers across the US, including partnerships for AI-driven clinical development in oncology.

Read more at Yahoo Finance: AstraZeneca announces $50bn US investment plans by 2030